Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
170 participants
OBSERVATIONAL
2002-03-31
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Levels of cortisol and norepinephrine increase in response to stress; these hormones also influence thought processes. This study will give hydrocortisone and/or yohimbine (a stimulator of central norepinephrine) to healthy adults in order to model the stress response and to better understand the way people process information during traumatic events.
This study comprises two experiments in which the stress response is pharmacologically modeled. Participants in the study will have two study visits. During Visit 1, participants will undergo a psychiatric assessment, complete neuropsychological tasks, and have their IQ measured. During Visit 2, participants will be given hydrocortisone and/or yohimbine. Blood will be collected before and during this. Participants will then perform two experiments. In one experiment, participants will hear a story with emotional and non-emotional segments; in a second experiment, participants will view both emotional and non-emotional stimuli.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Hydrocortisone on the Brain
NCT00055003
Role Of Sensitivity to neuroEndocrine Systems in Social Decisions
NCT06018727
Examining Cortisol and Alpha Amylase in a Healthy Sample of Youth and Adults
NCT02490280
Exploring the Effects of Corticosteroids on the Human Hippocampus
NCT03896659
Glucocorticoid Effects on Cellular Cytokine Release
NCT00001415
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Neurophysiologically, cortisol and norepinephrine are principal mediators of the stress response, and both influence memory function. In particular, cortisol improves memory at low levels but impairs memory at higher doses. Similarly, some evidence indicates that norepinephrine also enhances memory in low doses and either impairs or does not influence memory at high doses. Much of the experimental work in this area has been conducted with animals. Studies have recently begun to extend these paradigms to humans.
To better understand memory processing during trauma, hydrocortisone and/or yohimbine (a stimulator of central norepinephrine) will be administered to healthy adults in two experiments in order to pharmacologically model the stress response. Following infusion, participants will hear a story with emotional and nonemotional segments in one experiment (N = 80) and emotional as well as nonemotional stimuli (faces and scenes) in another experiment (N = 80). It is predicted that relative to the placebo, hydrocortisone will impair memory for both emotional and nonemotional information, yohimbine will improve memory for both types of information, and the combination of hydrocortisone and yohimbine will enhance memory for emotional aspects and impair memory for the nonemotional segments of the story. Results from this study will permit a better understanding of how emotionally charged memories are encoded and will potentially lead to treatments to mitigate the psychological effects of traumatic exposure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yohimbine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
IQ: all subjects will have IQ greater than 85
Follicular cycle: Women will participate in the encoding task between days 3-10.
Exclusion Criteria
Only healthy individuals will participate; special attention will be taken to ensure that no subject has: hypertension, glaucoma, cataracts, ulcers, renal insufficiency, osteoporosis, hypothyroidism, cirrhosis, ocular herpes simplex and myocardial infarction.
Use of hormonal contraception
Use of glucocorticoids within past 3 years
Use of any psychoactive substance; current or past psychiatric diagnosis.
Irregular sleep pattern as defined as getting less than 6 hours of sleep per night, going to sleep after 2:00 AM; waking up before 5:00 AM or after 11:00 AM
Weight that is 15% more or less than ideal body weight for sex and height
History of panic attacks or first degree relative with history of panic attacks
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Mental Health (NIMH)
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Diamond DM, Fleshner M, Ingersoll N, Rose GM. Psychological stress impairs spatial working memory: relevance to electrophysiological studies of hippocampal function. Behav Neurosci. 1996 Aug;110(4):661-72. doi: 10.1037//0735-7044.110.4.661.
Sandi C, Loscertales M, Guaza C. Experience-dependent facilitating effect of corticosterone on spatial memory formation in the water maze. Eur J Neurosci. 1997 Apr;9(4):637-42. doi: 10.1111/j.1460-9568.1997.tb01412.x.
Christianson SA, Fallman L. The role of age on reactivity and memory for emotional pictures. Scand J Psychol. 1990;31(4):291-301. doi: 10.1111/j.1467-9450.1990.tb00841.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02-M-0155
Identifier Type: -
Identifier Source: secondary_id
020155
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.